Actively Recruiting
Randomized Study of ALV-100 Versus Placebo to Maintain Weight Loss in Adults Previously Treated with Incretin-Based Therapies
Led by Alveus Therapeutics, Inc. · Updated on 2026-10-26
220
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ALV-100 in adults with overweight or obesity who have already achieved at least a 10% weight loss while using incretin-based therapies. This phase 2 study aims to assess the effect, safety, and tolerability of ALV-100 in maintaining weight loss compared to a placebo. The study focuses on participants aged 18 to 75 years with a body mass index BMI of 23 kgm2 or higher who have been on stable incretin-based therapy for at least 3 months. Participants are randomly assigned to receive one of several doses of ALV-100 or a volume-matched placebo during the treatment period. The study is double-blind and multi-center, with four different experimental dose schedules being evaluated. The primary treatment period lasts 24 weeks, with additional monitoring extending up to 36 weeks to assess safety, tolerability, and various metabolic and behavioral outcomes. During the study, participants will be monitored for maintenance of weight loss, changes in blood sugar control, lipid levels, vital signs, and eating behaviors using questionnaires. Safety assessments include immunogenicity and overall tolerability of ALV-100. Participants are expected to maintain their usual diet and physical activity throughout the study. The total study duration for each participant can last up to 36 weeks, including follow-up evaluations to ensure comprehensive assessment of the study drugs effects.
CONDITIONS
Brief Title
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here